Deutsche Bank maintains a Sell rating on Intuitive Surgical and lowers the target price to $324

Overview

This is a Deutsche Bank company update report on Intuitive Surgical, with the core conclusion to maintain a Sell rating and lower the target price. The report focuses on 2Q procedure volume, system placements, overseas competition, pressure on I&A revenue/procedure volumes, and valuation risk. Although dV5 demand in the US remains healthy and total system placements exceeded expectations, weaker-than-expected US procedure growth, intensifying competition in overseas markets such as China and India, and lower-priced remanufactured instruments and Extended Use may weaken the high-margin I&A business model.

Core views

The report’s core view is that ISRG’s fundamentals no longer show the historically strong pattern of consistently beating expectations and raising guidance. US da Vinci procedure growth was below expectations, and full-year procedure guidance was not raised; system placements and procedure growth in China have been hit by domestic low-cost platforms; the Indian market is also seeing local and Chinese low-cost systems gain share; and the I&A business faces dual pressure from Extended Use and remanufactured instruments. Deutsche Bank believes these factors will weigh on revenue growth in 2027-2028 and weaken the moat that supports ISRG’s valuation premium.

Analysis framework

The report uses a framework combining quarterly earnings review, company guidance comparison, consensus comparison, channel checks, and relative valuation. The analysis focuses on procedure growth, system placements, net installed base, I&A revenue/procedure volumes, overseas competitive dynamics, hospital capital spending pressure, and PEG premium valuation versus high-quality large-cap medtech peers.

Methodology notes

• Valuation methodsPEG relative valuation

  Using high-quality large-cap medtech peers as the benchmark, ISRG is assigned a 75% PEG premium.

  The report states that the $324 target price is based on its valuation framework, which continues to assume that ISRG deserves a 75% PEG premium relative to high-quality large-cap medtech peers such as SYK, EW, and MDLN.

• Fundamental analysisProcedure and placement driver analysis

  Assessing growth quality through global and US procedure volumes, system placements, net installed base, and regional placement changes.

  The report believes 2Q global procedure growth of about 15% was broadly in line with expectations, but the 12% US growth rate missed expectations, and the sharp drop in China placements shows pressure on the quality of overseas growth.

• Competitive analysisI&A moat pressure assessment

  Evaluating the potential impact of Extended Use, remanufactured instruments, and low-cost robotic platforms on I&A revenue per procedure.

  The report believes higher adoption of remanufactured instruments and the second round of Extended Use may reduce instrument revenue per procedure, thereby weakening ISRG’s high-margin I&A business.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Intuitive Surgical (ISRG.OQ)

  The company covered by the report; Deutsche Bank maintains a Sell rating and lowers the target price.

  Strengths

  dV5 demand remains healthy in the US, 2Q total system placements exceeded consensus expectations, and the ASC channel gained momentum from the XiR launch.

  Weaknesses

  US procedure growth was below expectations, China placements slowed sharply, net installed base growth is decelerating, and I&A revenue/procedure volumes face pressure from Extended Use and remanufactured instruments.

  Comparison

  The valuation framework compares ISRG with high-quality large-cap medtech peers such as SYK, EW, and MDLN, while still assuming a 75% PEG premium.

  Risks

  If adoption of remanufactured instruments is lower than expected, third-party remanufacturers execute poorly, or procedure volume or dV5 placements materially exceed expectations, these could present upside risk to the Sell rating and target price.

• China and India robotic surgery markets

  Key overseas growth regions for ISRG and sources of competitive pressure.

  Strengths

  India delivered strong 2Q procedure volume performance, and dV5 has received regulatory approval in India.

  Weaknesses

  Intensifying competition from domestic platforms in China has lowered da Vinci’s bid-win rate; hospital system checks in India show local and Chinese low-cost systems continue to gain placement share.

  Comparison

  The report believes low-cost Indian and Chinese systems are challenging ISRG’s share and growth in key OUS markets.

  Risks

  If low-cost competition continues to spread, ISRG’s overseas system placements and procedure growth may continue to slow.

Key data

• RatingSellDeutsche Bank maintains its Sell rating.
• Target price$324.00Cut from $366.00 to $324.00, a decline of about 11.5%.
• Current price$402.33As of July 16, 2026.
• Implied return potentialabout -19.5%Roughly calculated using the $324 target price and the current price of $402.33.
• 2Q global procedure growth+15%Broadly in line with consensus expectations.
• 2Q US procedure growth+12%Below expectations; management mentioned ACA subsidy cuts affecting some elective robotic surgery categories.
• Full-year global procedure growth guidance+13.5% to +15.5%The company maintained guidance, and the report believes the growth trend is near the midpoint of the range.
• Total system placements468 unitsAbove the consensus expectation of 446 units, reflecting still-healthy US dV5 demand.
• China placements2Q 2 units, 6 units year-to-dateSignificantly below 29 units in 1H25, and the report believes domestic platform competition has reduced da Vinci’s bid-win rate.
• Share of remanufactured monopolar scissorsabout 5% to 7%The report estimates this remanufactured category has already captured that level of share, and monopolar scissors account for about 14% of I&A segment sales.

Impact & implications

The report is negative in investment implications: if procedure growth lacks upside, overseas market placements continue to be eroded by low-cost competition, and I&A revenue/procedure volumes come under pressure in 2027-2028, then ISRG’s current high valuation premium may be difficult to sustain. In the near term, US dV5 demand and the ASC channel remain supporting factors, but they are insufficient to offset the slowdown in growth and moat erosion risks emphasized in the report.

Risks

• Upside risks to the target price include commercial execution missteps by third-party remanufacturers.
• Lower-than-expected adoption of remanufactured instruments could ease pressure on I&A revenue.
• Procedure growth, dV5 placements, or net installed base growth materially better than expected could drive fundamental upside.
• Pressure on hospital profit margins may lead to cuts in capital spending budgets, posing a risk to system sales.
• Competition from low-cost robotic platforms in China and India may continue to pressure ISRG’s overseas placements and growth.
• The second round of Extended Use could create a meaningful drag on I&A revenue/procedure volumes in 2027-2028.

What to watch

• Whether full-year global procedure growth remains near the midpoint of the 13.5% to 15.5% range.
• Whether elective robotic surgery categories in the US continue to be affected by ACA subsidy cuts or changes in hospital utilization.
• Whether dV5 placement momentum and net installed base growth in the US slow.
• China’s da Vinci bid-win rate, quarterly placement volume, and the competitive dynamics of domestic platforms.
• Actual adoption after dV5 approval in India, as well as changes in share for local and Chinese low-cost systems.
• The specific instruments covered in the second round of Extended Use in 1H27, the number of permitted uses, and the quantified impact on I&A revenue/procedure volumes.
• Subsequent FDA approvals and hospital adoption rates for remanufactured instruments, especially additional categories beyond monopolar scissors.